Targeted Colostrum Bioactive Proteins Improve Gastrointestinal Symptoms and Modulate the Gut Microbiome: A Randomised Double-Blind Placebo-Controlled Trial
4 affiliations
- 1RDC Clinical, Brisbane 4006, Australia
- 2Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv 6997801, Israel
- 3Shamir Medical Center, Zerifin 7033001, Israel
- 4School of Health, Medical and Applied Sciences, Central Queensland University, Rockhampton 4702, Australia
Abstract
Background: Gastrointestinal (GI) symptoms such as indigestion, bloating and reflux are common and can negatively affect quality of life. Bovine colostrum is a rich source of nutrients and other bioactive constituents that has been shown to be beneficial for gut health. Methods: This 12-week, randomised, double-blind, placebo-controlled, 3-arm study aimed to evaluate the effects of MaolactinGI™, a proprietary bovine colostrum supplement, on upper GI symptoms and gut microbiome composition in healthy adults aged 18 years and older experiencing moderate GI discomfort. Participants completed a 4-week run-in period followed by an 8-week intervention period. Outcomes measured included changes in upper GI symptoms via the Gastrointestinal Symptom Rating Scale (GSRS), Gastroesophageal Reflux Disease Questionnaire (GerdQ), Bloating Symptoms Visual Analogue Scale (BSVAS), Digestion-associated Quality of Life Questionnaire (DQLQ), Bristol Stool Chart, intestinal permeability, faecal calprotectin, serum inflammatory markers, gut microbiome analyses, blood safety markers and adverse events. Results: Ninety eligible participants were allocated to either the high-dose (500 mg/day), low-dose (250 mg/day), or placebo groups, and data from 83 participants were analysed. The high-dose MaolactinGI™ group demonstrated statistically significant improvements in the total GSRS score and DQLQ score compared with placebo, suggesting a meaningful reduction in total symptom burden and improved quality of life. The improvements in GSRS were clinically meaningful in size, supporting the practical relevance of MaolactinGI™ for adults experiencing everyday upper GI discomfort. High-dose supplementation also preserved microbial richness relative to placebo (Chao1); exploratory within-group analyses further indicated enrichment of SCFA-associated commensal taxa. The intervention was well tolerated and demonstrated an acceptable safety profile. Conclusions: These findings support the potential of targeted colostrum-derived bioactive protein fractions as a novel nutritional strategy for supporting GI health and microbiome balance.
Related
- Enterotoxigenic Escherichia coli hyperimmune bovine colostrum for preventing travellers’ diarrhoea (TD): a randomised, double-blind, placebo-controlled trial
- Implementing a medical opinion leader-led management model to promote timely treatment initiation among screen-positive patients with upper gastrointestinal cancer in rural China: a cluster randomised controlled trial protocol
- Thymus serpyllum Extract Improves Gastrointestinal Symptoms and Modulates Fecal Gut Microbiome Composition in a Multicenter, Randomized, Placebo-Controlled Clinical Trial.
- Brainstem functional connectivity integrates microbiome-gut-brain signals in healthy older adults: a cross-sectional evaluation and a randomised controlled probiotic trial
- Acupuncture for older adults with dementia in residential care homes: an assessor-blinded, randomised controlled trial
BibTeX
@article{rao2026targeted,
title = {{Targeted Colostrum Bioactive Proteins Improve Gastrointestinal Symptoms and Modulate the Gut Microbiome: A Randomised Double-Blind Placebo-Controlled Trial}},
author = {Amanda Rao and Tzippora Shalem and Romeo Batacan and Yadav Sharma Bajagai and David Briskey},
journal = {Nutrients},
year = {2026},
month = oct,
doi = {10.3390/nu18213561},
url = {https://www.mdpi.com/2072-6643/18/21/3561},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Targeted Colostrum Bioactive Proteins Improve Gastrointestinal Symptoms and Modulate the Gut Microbiome: A Randomised Double-Blind Placebo-Controlled Trial
AU - Amanda Rao
AU - Tzippora Shalem
AU - Romeo Batacan
AU - Yadav Sharma Bajagai
AU - David Briskey
PY - 2026
DA - 2026/10/28
JO - Nutrients
DO - 10.3390/nu18213561
UR - https://www.mdpi.com/2072-6643/18/21/3561
AB - Background: Gastrointestinal (GI) symptoms such as indigestion, bloating and reflux are common and can negatively affect quality of life. Bovine colostrum is a rich source of nutrients and other bioactive constituents that has been shown to be beneficial for gut health. Methods: This 12-week, randomised, double-blind, placebo-controlled, 3-arm study aimed to evaluate the effects of MaolactinGI™, a proprietary bovine colostrum supplement, on upper GI symptoms and gut microbiome composition in healthy adults aged 18 years and older experiencing moderate GI discomfort. Participants completed a 4-week run-in period followed by an 8-week intervention period. Outcomes measured included changes in upper GI symptoms via the Gastrointestinal Symptom Rating Scale (GSRS), Gastroesophageal Reflux Disease Questionnaire (GerdQ), Bloating Symptoms Visual Analogue Scale (BSVAS), Digestion-associated Quality of Life Questionnaire (DQLQ), Bristol Stool Chart, intestinal permeability, faecal calprotectin, serum inflammatory markers, gut microbiome analyses, blood safety markers and adverse events. Results: Ninety eligible participants were allocated to either the high-dose (500 mg/day), low-dose (250 mg/day), or placebo groups, and data from 83 participants were analysed. The high-dose MaolactinGI™ group demonstrated statistically significant improvements in the total GSRS score and DQLQ score compared with placebo, suggesting a meaningful reduction in total symptom burden and improved quality of life. The improvements in GSRS were clinically meaningful in size, supporting the practical relevance of MaolactinGI™ for adults experiencing everyday upper GI discomfort. High-dose supplementation also preserved microbial richness relative to placebo (Chao1); exploratory within-group analyses further indicated enrichment of SCFA-associated commensal taxa. The intervention was well tolerated and demonstrated an acceptable safety profile. Conclusions: These findings support the potential of targeted colostrum-derived bioactive protein fractions as a novel nutritional strategy for supporting GI health and microbiome balance.
SN - 2072-6643
ER -